Thrombophilia classification: Difference between revisions
Jump to navigation
Jump to search
reformatting |
No edit summary |
||
| Line 7: | Line 7: | ||
==Classification== | ==Classification== | ||
*Thrombophilia can be classified | *Thrombophilia can be classified into three subtypes<ref name=?>Hoffman R, Benz EJ, Shattil SJ, et al. Hematology: Basic Principles and Practice: Elsevier Science Health Science Division; 2004.</ref><ref name="pmid24421360">{{cite journal| author=Cohoon KP, Heit JA| title=Inherited and secondary thrombophilia. | journal=Circulation | year= 2014 | volume= 129 | issue= 2 | pages= 254-7 | pmid=24421360 | doi=10.1161/CIRCULATIONAHA.113.001943 | pmc=3979345 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24421360 }} </ref> | ||
:*Inherited thrombophilia or primary hypercoagulable state | :*Inherited thrombophilia or primary hypercoagulable state | ||
:*Acquired thrombophilia or secondary hypercoagulable state | :*Acquired thrombophilia or secondary hypercoagulable state | ||
| Line 40: | Line 40: | ||
| Increased factor IX levels | | Increased factor IX levels | ||
|- | |- | ||
| | | Non-O blood type | ||
| Myeloproliferative disorders (polycythemia vera, essential thrombocythemia, hyperviscosity) | | Myeloproliferative disorders (polycythemia vera, essential thrombocythemia, hyperviscosity) | ||
| Increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) | | Increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) | ||
| Line 97: | Line 97: | ||
|- | |- | ||
| | | | ||
| Drug related (chemotherapies including L-aspariginase, mitomycin | | Drug related (chemotherapies including L-aspariginase, mitomycin; infusion of clotting factors including prothrombin complex concentrates, cryoprecipitate; drugs including hydralazine, procainamide, or phenothiazines can promote lupus anticoagulant formation) | ||
| | | | ||
|} | |} | ||
| Line 117: | Line 117: | ||
|- | |- | ||
| style="text-align: center;" | Hyperhomocysteinemia | | style="text-align: center;" | Hyperhomocysteinemia | ||
|} | |} | ||
Revision as of 19:51, 25 June 2016
|
Thrombophilia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thrombophilia classification On the Web |
|
American Roentgen Ray Society Images of Thrombophilia classification |
|
Risk calculators and risk factors for Thrombophilia classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Asiri Ediriwickrema, M.D., M.H.S. [2]
Overview
Thrombophilias are classified as either inherited or a primary hypercoagulable state, acquired or a secondary hypercoagulable state, or mixed/unknown. Certain conditions are associated with greater thrombotic risks and both venous and arterial clots.
Classification
- Inherited thrombophilia or primary hypercoagulable state
- Acquired thrombophilia or secondary hypercoagulable state
- Mixed/Unknown
- Different thrombophilic states are associated with venous or both venous and arterial clots
| Thrombophilia Classification | ||
|---|---|---|
| Inherited (Primary) | Acquired (Secondary) | Mixed/Unknown |
| Activated protein C (APC) resistance (Factor V Leiden) | Age | Hyperhomocysteinemia |
| Prothrombin gene mutation (Prothrombin G20210A) | Immobilization | APC resistance unrelated to Factor V Leiden. |
| Antithrombin deficiency | Trauma/major surgery | Increased factor VIII levels |
| Protein C and protein S deficiency | Orthopedic surgery | Increased factor XI levels |
| Dysfibrinogenemia | Malignancy | Increased factor IX levels |
| Non-O blood type | Myeloproliferative disorders (polycythemia vera, essential thrombocythemia, hyperviscosity) | Increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) |
| Pregnancy | Decreased levels of free tissue factor pathway inhibitor (TFPI) | |
| Estrogen and testosterone (oral contraceptives, hormone replacement therapy, and selective estrogen receptor modulator) | ||
| Obesity | ||
| Heart Failure | ||
| Cirrhosis | ||
| Chronic renal disease (nephrotic syndrome) | ||
| Antiphospholipid syndrome (APLS) or lupus anticoagulant | ||
| Heparin induced thrombocytopenia (HIT) | ||
| Disseminated intravascular coagulopathy (DIC) | ||
| Paroxysmal nocturnal hemoglobinuria (PNH) | ||
| Autoimmune disorders (Vasculitis, celiac's disease, inflammatory bowel disease) | ||
| Thrombotic microangiopathy | ||
| Sickle cell disease | ||
| Drug related (chemotherapies including L-aspariginase, mitomycin; infusion of clotting factors including prothrombin complex concentrates, cryoprecipitate; drugs including hydralazine, procainamide, or phenothiazines can promote lupus anticoagulant formation) | ||
| Thrombophilic states associated with arterial clots |
|---|
| APLS and lupus anticoagulant |
| HIT |
| DIC |
| PNH |
| Cold agglutinins (associated with mycoplasma infections) |
| Vasculitis |
| Hyperhomocysteinemia |
| Thrombophilic state | Thrombotic risk[3] |
|---|---|
| Trauma/General surgery | Modest |
| Age > 60 | Modest |
| Immobilization | Modest |
| Pregnancy | Modest |
| Hormone therapies | Modest |
| Factor V Leiden heterozygosity | Modest |
| Prothrombin mutation | Modest |
| Homocysteinemia | Modest |
| Increased factor VIII levels | Modest |
| Increased factor IX levels | Modest |
| Increased factor XI levels | Modest |
| Protein C and S deficiency | Intermediate |
| Dysfibrogenemia | Intermediate |
| Malignancy | High |
| APLS/Lupus anticoagulant | High |
| Myeloproliferative disorders/hyperviscosity | High |
| PNH | High |
| Orthopedic surgery | High |
| Antithrombin deficiency | High |
| Factor V Leiden homozygosity | High |
References
- ↑ Hoffman R, Benz EJ, Shattil SJ, et al. Hematology: Basic Principles and Practice: Elsevier Science Health Science Division; 2004.
- ↑ Cohoon KP, Heit JA (2014). "Inherited and secondary thrombophilia". Circulation. 129 (2): 254–7. doi:10.1161/CIRCULATIONAHA.113.001943. PMC 3979345. PMID 24421360.
- ↑ Bates SM, Ginsberg JS (2004). "Clinical practice. Treatment of deep-vein thrombosis". N Engl J Med. 351 (3): 268–77. doi:10.1056/NEJMcp031676. PMID 15254285.